Evidence map›Paper›PMID 41098110›Full record

ArticleHaematologica2026

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Mengyao Yuan, Li Zhou, Weiming Li, Xin Du, Jianyu Weng, Linhua Yang, Yanping Ma, Bingcheng Liu, Zhenfang Liu, Qin Wen and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Mengyao YuanPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, 100044, Beijing.
Li ZhouShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai.
Weiming LiDepartment of Hematology, Union hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan.
Xin DuDepartment of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 519041, Guangzhou.
Jianyu WengDepartment of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 519041, Guangzhou.
Linhua YangDepartment of Hematology, Second Hospital of Shanxi Medical University, Taiyuan.
Yanping MaDepartment of Hematology, Second Hospital of Shanxi Medical University, Taiyuan.
Bingcheng LiuNational Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 030001, Tianjing.
Zhenfang LiuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, 530021, Guangxi.
Qin WenMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, 400030, Chongqing.
Shasha ZhaoPeking University People's Hospital, 266111, Qingdao.
Yanli ZhangDepartment of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, 450008, Henan.
Qingxian BaiDepartment of Hematology, Xijing Hospital, 710000, Shanxi.
Xianqi FengDepartment of Hematology, The Affiliated Hospital of Qingdao University, 266000, Qingdao.
Yanqiu HanDepartment of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, 010030, Inner Mongolia.
Chunshui LiuDepartment of Hematology, The First Hospital of Jilin University, 130031, Jilin.
Li MengDepartment of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, 430030, Wuhan.
Baohong WangDepartment of Hematology, Weifang People's Hospital, 261041, Weifang.
Xuehong RanDepartment of Hematology, Weifang People's Hospital, 261041, Weifang.
Xiaodong WangDepartment of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, 610072, Sichuan.
Haiguo ZhangDepartment of Hematology, Jining No.1 People's Hospital, 272011, Jining.
Yun ZengDepartment of Hematology, First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, 650032, Kunming.
Qing LengAnshan Central Hospital, 114001, Anshan.
Lu YuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, 100044, Beijing.
Zongru LiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, 100044, Beijing.
Robert Peter GalePeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, 100044, Beijing, China; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, SW72az, London, United Kingdom.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, 100044, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, 100871, Peking University, Beijing.
Qian JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, 100044, Beijing, China; Peking University People's Hospital, 266111, Qingdao. jiangqian@medmail.com.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied 130 consecutive subjects who presented with (N=29) or transformed to (N=101) accelerated-phase chronic myeloid leukemia (CML) and who received olverembatinib. Sixty-two were in second chronic phase. All failed ≥1 tyrosine kinase inhibitor (TKI) and 91 had BCR::ABL1T315I. Median follow-up was 28 months (interquartile range, 10-74 months). The 6-year cumulative incidences of major cytogenetic response (MCyR), complete cytogenetic response, major molecular response and molecular response 4.0 were 59% (95% confidence interval [CI]: 49- 69), 53% (95% CI: 42-62), 52% (95% CI: 41-62) and 42% (95% CI: 31- 53), respectively. The 6-year probabilities of transformation-free survival (TFS), CML-related survival and survival were 81% (95% CI: 72-90), 76% (95% CI: 67-87%) and 71% (95% CI: 61-82), respectively. In multi-variable analyses, an interval from diagnosis of CML to olverembatinib start <29 months, failure to achieve complete hematologic response on prior TKI therapy, hemoglobin concentration <98 g/L, blood and/or bone marrow blasts ≥8%, and/or high-risk additional chromosome abnormalities at the start of olverembatinib therapy, as well as not achieving early MCyR on olverembatinib correlated with worse outcomes. RUNX1 and STAT5A variants were significantly associated with worse TFS in the 82 subjects with targeted DNA-sequencing data. There were acceptable treatment-related adverse events. We conclude olverembatinib is effective and tolerable in subjects in accelerated-phase CML failing prior TKI therapy.

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, Accelerated PhaseProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleFollow-Up StudiesFusion Proteins, bcr-ablHumansMaleMiddle AgedTreatment OutcomeAntineoplastic AgentsFusion Proteins, bcr-ablProtein Kinase Inhibitors

Identifiers

PMID41098110
PMCPMC12951141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.